Fig. 1: Flow diagram of the study.

On the left: the clinical cohort of our study (n = 247) in which we identified the propensity-score matched population of patients treated with anthracycline-taxane (AT) chemotherapy with or without carboplatin (AT-Cb). On the right: the translational cohort were we evaluated tumor-infiltrating lymphocytes (TILs) at baseline (n = 163) and on residual disease (RD-TILs, n = 96), assessing the delta TIL variation.